Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/541,268external-prioritypatent/US6270755B1/en
Priority claimed from US09/569,276external-prioritypatent/US6290946B1/en
Application filed by Genzyme CorpfiledCriticalGenzyme Corp
Publication of AR026446A1publicationCriticalpatent/AR026446A1/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
La presente se relaciona con un método de inhibicion de una toxina en un animal, tal como un humano, mediante administracion al animal de una cantidadterapéuticamente efectiva de un polímero que tiene una pluralidad de grupos ácido-funcionales penden ientes que están directamente unidos al esqueletopolimérico o unidos al esqueleto polimérico a través de un grupo espaciador. El grupo espaciador puede tener una longitud en el rango de 0 a proximadamente 20átomos. La toxina es típicamente una exotox ina segregada por un microorganismo patogeno, tal como una bacteria.This is related to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendent acid-functional groups that are directly attached to the skeletholimeric or attached to the polymeric skeleton through a spacer group. The spacer group may have a length in the range of 0 to about 20 atoms. The toxin is typically an exotox ina secreted by a pathogenic microorganism, such as a bacterium.
ARP000105970A2000-04-032000-11-13
ANIONIC POLYMERS AS BINDERS OF TOXINS AND ANTIBACTERIAL AGENTS
AR026446A1
(en)
Use of mupirocin in the manufacture of a medicament for the treatment of bacterial infections associated with colonization of the nasopharynx by pathogenic organisms.